About the role
About Parabilis Medicines Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact. For more information, visit www.parabilismed.com or follow us on LinkedIn . What’s the opportunity? This newly created role is critical to the finance and accounting function and includes primary responsibility for preparing monthly and quarterly internal and external financial statements and related analyses. This role will also take the lead regarding technical accounting matters, with or without the assistance of external advisors depending on the matter. This role will also be involved with the implementation and maintenance of the department’s formal structure of internal controls over financial reporting (ICFR). This role calls for performing rigorous technical research and developing welldocumented memos, executive-ready analyses, and implementation approaches that support confident, flexible decision-making. In doing so, this role protects the integrity of our financial reporting, supports compliant growth, and advances the strategic objectives of the finance and accounting organization and the broader company. This role reports to the Company’s VP of Finance/Corporate Controller. Lead preparation of annual reports on Form 10-K, quarterly reports on Form 10-Q, and assist with other SEC filings (8-K, proxy statement, Form 4, S-8, S-1). Manage draft review cycles across internal colleagues, auditors, and external legal counsel, helping consolidate comments and move filings through completion. Contribute to monthly and quarterly analysis of financial results, providing insights to drive business decisions. Conduct technical accounting research and assessments of complex transactions (including collaboration arrangements), draft related memos, and coordinate assessments performed by external advisors; support the ongoing accounting for collaboration arrangements, including monthly revenue calculations, gathering expense information, and partnering with Business Development and Research to ensure accurate financial reporting. Assess the impacts of new accounting pronouncements and prepare implementation plans. Support business development, FP&A, and other colleagues by researching and concisely communicating the accounting and financial statement impacts of proposed opportunities. Play a significant role in the Company’s implementation of a formal structure of ICFR with assistance from external advisors, and in periodic maintenance thereof (control testing, deficiency assessments, changes, etc.). Function as a key liaison for external auditors in areas of responsibility. Assist with monthly and quarterly financial close processes as needed. Work on special projects and initiatives as needed. Interact with all other finance and accounting team members and colleagues from other departments. What you’ll need to be successful: Bachelor’s degree in accounting or related area CPA license strongly preferred Five to eight years of relevant experience, including in public accounting (“Big 4” firm preferred) and/or in industry, with experience in the biotechnology or pharmaceutical industry preferred. Strong knowledge of U.S. GAAP, U.S. Securities and Exchange Commission rules and principles, public company financial statement disclosure
